With unrestricted educational grant from



Similar documents
Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

Thrombosis and Hemostasis

Investor News. Not intended for U.S. and UK media

Center of Excellence in Naturopathic Cardiovascular Medicine

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

From Concept to a Published Paper - a guide to excellence in Medical Research.

June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP S. Wabash Suite 203. Chicago, Illinois

Prior Authorization Guideline

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, Committee Approval Date: July 11, 2014 Next Review Date: July 2015

21st Annual OSF Cardiovascular Symposium

Bringing Science to Clinical Practice: BEST OF ACC 2015

2014 Emerging Faculty Participants

Minimally Invasive Cardiac Surgery

7th annual ConFerenCe location

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, Participating Faculty

CHAPTER. 9th Annual Meeting October 12, :00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky

Gruppo di lavoro: Malattie Tromboemboliche

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Brooklyn Stroke Symposium 2015

Duke Regional Diabetes Symposium 2012

ABOUT XARELTO CLINICAL STUDIES

2012 Innovations in Heart Failure and Pulmonary Hypertension

EXHIBITOR PROSPECTUS

Cardiac Care Associates 2014 Annual Meeting

CARDIOLOGY UPDATE 2004

23 rd Annual Conference on Cardiovascular Nursing

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

DVT/PE Management with Rivaroxaban (Xarelto)

Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Anticoagulation at the end of life. Rhona Maclean

STROKE PREVENTION IN ATRIAL FIBRILLATION

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

INTRODUCTION. For supporting information, we invite you to explore. Our Corporate Website. and its Media Center

HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas

Cardiac Rehabilitation: Strategies Approaching 2020

A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m.

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

AnMed Health Disparities Dashboard

FRIDAY, FEBRUARY 26, :15 A.M. TO 3:15 P.M.

2016 Cardiovascular Update

Heart Failure: From Prevention to Intervention

Establishing a Course of Excellence. Duvall, WA Or Complete This Form and Return. PH: to Gaffney Events

Backgrounder. Current anticoagulant therapies

EXHIBITOR PROSPECTUS

New Oral Anticoagulants. How safe are they outside the trials?

May 20, May 21, The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium

CURRICULUM VITAE. NAME: Stephen Harold Arnold Hernandez, PhD, RN

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

24 th Annual Conference on Cardiovascular Nursing

Curriculum Vitae Statonsburg Road (252)

FACULTY OF ALLIED HEALTH SCIENCES

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Antiplatelet and Antithrombotics From clinical trials to guidelines

Updates to the Alberta Human Services Drug Benefit Supplement

AMERICAN COLLEGE of CARDIOLOGY

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

Coronary CTA in the Emergency Department A Hands-on Workshop

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, Participating Faculty

About Medicine Specialists of Florida Hospital:

24 th Annual Frontiers in Critical Care Nursing. Presented by UMass Memorial Medical Center Heart and Vascular Center of Excellence

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

San Antonio Heart Failure Symposium 2015

xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

Service Specification Template Department of Health, updated June 2015

PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Anticoagulation before and after cardioversion; which and for how long

Tennessee Chapter Scientific Meeting

STEMI & CARDIAC ARREST

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Sanford Health/UNDSMHS Cerebrovascular Symposium

Cardiovascular Subcommittee of PTAC Meeting held 27 February (minutes for web publishing)

Transcription:

HOTEL MAKSOUD PLAZA SÃO PAULO SP BRASIL OCTOBER 22-23, 2009

Organization With unrestricted educational grant from

As the President of the Brazilian Society of Internal Medicine and the Brazilian Clinical Research Institute (BCRI) I am honored to welcome you to the 2 nd. International Symposium of Thrombosis and Anticoagulation ISTA 2009. The main purpose of this symposium is to discuss the most recent evidence on thrombosis and anticoagulation, including new agents under development and novel diagnostic tools in the field. The focus is to understand how to better apply the evidence into clinical practice so that the patients will gain and you will enhance the quality of care you offer your patients. This meeting provides a unique opportunity to witness the latest knowledge in this field. The clinical aspects including the most update treatments are our major objective in order to offer you concise answers that will help in the patient management on a day-by-day basis. I Hope you enjoy this scientific program and take advantage of the presence of our expert national and international faculty. Antonio Carlos Lopes, MD, PhD, FACP Brazilian Society of Internal Medicine President

Co-Chairs Becker, Richard C. MD Lopes, Renato D. MD, MHS, PhD Federal University of Sao Paulo (UNIFESP-EPM) International Faculty Alexander, John H. Garcia, David University of New Mexico (USA) Granger, Christopher B. Handller, Allison Jolicoeur, E. Marc Montreal Heart Institute (Canada) Newby, L. Kristin Pieper, Karen S. National Faculty Baruzzi, Antonio Claudio Carvalho, Antonio Carlos Chamone, Dalton de Alencar F. Guimarães, Hélio Penna Lopes, Antonio Carlos Machado, Fabio Santana Timerman, Ari

Scientific Program OCTOBER 22, 2009 09:00 09:10 Opening Antonio Carlos Lopes, Richard C. Becker, and Renato D. Lopes SESSION I President: Christopher B. Granger 09:10 09:30 Update in Thrombosis and Anticoagulation in Clinical Practice Richard C. Becker 09:40 10:00 Biomarkers of Thrombosis - How and Which one to Use? L. Kristin Newby 10:10 10:30 Anticoagulation in Acute Coronary Syndromes Ari Timerman 10:30 10:50 Coffee Break 10:50 11:10 Triple Therapy - A Management Dilemma Renato D. Lopes 11:20 11:40 Stroke: Should We use Antithrombotics? When and How? Fabio Santana Machado 11:40 12:00 Challenging Cases David Garcia 12:00 14:00 Break SESSION II President: E. Marc Jolicoeur 14:00 15:20 Thrombosis in: Diabetes: L. Kristin Newby Atrial Fibrillation: John H. Alexander Dyslipidemia: Christopher B. Granger Heart Failure/Hypertension: Antonio Carlos Carvalho 15:30 15:50 Management of Bleeding Episodes in Patients receiving Antithrombotic Therapy David Garcia 16:00 16:30 Coffee Break 16:30 17:00 Design Issues and Statistical Considerations around Clinical Research Karen Pieper 17:10 17:40 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

OCTOBER 23, 2009 SESSION III President: Antonio Carlos Lopes 09:00 09:20 VTE prophilaxis in Medical Patients Renato D. Lopes 09:25 09:55 Treatment for VTE Dalton de Alencar F. Chamone 10:00 10:20 Post-thrombotic Syndrome: Epidemiology and Management Richard C. Becker 10:20 10:40 Coffee Break 10:40 11:10 Predicting Cancer Patients at Risk for Venous Thromboembolism: Strategies for Prophylaxis David Garcia 11:15 11:45 Diagnosis and Management of Pulmonary Embolism Antonio Claudio Baruzzi 11:50 12:10 How to Better Interpret the Medical Literature? Karen Pieper 12:15 12:45 Challenging Cases L. Kristin Newby 12:45 14:00 Break SESSION IV President: Christopher B. Granger 14:00 14:20 Globalization of Clinical Research John H. Alexander 14:30 15:00 Anticoagulation in Special Patient Populations E. Marc Jolicoeur 15:10 15:30 Anticoagulation in Intensive Care Units Hélio Penna Guimarães 15:40 16:00 Coffee Break 16:00 16:20 The Latest ACCP Antithrombotic Therapy Guidelines: Important Changes that may Impact Clinical Practice David Garcia 16:30 16:50 Importance of Academic Coordinating Center in Clinical Trials in Thrombosis Allison Handller 17:00 17:30 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

SBCM President and Co-Chairs Antonio Carlos Lopes, MD, PhD, FACP 4 Full Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 Full Professor of Emergency Medicine, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo Paulista School of Medicine 4 President of the Brazilian Society of Internal Medicine 4 President of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Physicians Richard C. Becker, MD 4 Professor of Medicine. Divisions of Cardiology and Hematology, Department of Medicine - Duke University Medical Center 4 Director of the Duke Cardiovascular Thrombosis Center Duke Clinical Research Institute (DCRI) 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) Renato Delascio Lopes MD, MHS, PhD 4 Adjunct Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Assistant Director - Clinical Research Fellowship Program Duke Clinical Research Institute (DCRI) 4 Assistant Professor - Department of Internal Medicine Federal University of Sao Paulo - Paulista School of Medicine 4 Executive Director - Brazilian Clinical Research Institute (BCRI)

Invited Speakers Christopher B. Granger, MD, FACC 4 Professor of Medicine - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director, Cardiac Care Unit - Duke University Medical Center 4 Co-Director of Cardiovascular Clinical Trials Duke Clinical Research Institute L. Kristin Newby, MD, MHS 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Co-director of the Cardiac Care Unit Duke University Hospital 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) John Alexander, MD, MHS, FACC 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director of Early Phase Cardiovascular Research Duke Clinical Research Institute (DCRI) 4 Medical director of Site-Based Clinical Research in Cardiovascular Medicine Duke University Medical Center David Garcia, MD 4 Associate Professor - Department of Internal Medicine Division of Hematology/Oncology University of New Mexico Health Sciences Center 4 Director of Cancer and Thrombosis at the University of New Mexico Cancer Center - Director of the Anticoagulation Management Service at University Hospital

Invited Speakers E. Marc Jolicœur, MD, MSc, FRCP 4 Assistant Professor - Division of Cardiology, Department of Medicine - University of Montreal 4 Research Associate, University of Montreal Karen S. Pieper, MS 4 Associate Director for Faculty and Fellow Affairs and Clinical Trials Statistical Operations. Duke Clinical Research Institute (DCRI) Allison Handller RN, BSN, MS 4 Senior Project Leader Cardiovascular Devices Phase III/IV Cardiovascular Mega trials Duke Clinical Rsearch Institute (DCRI) Antonio Carlos Carvalho, MD, PhD, FACC 4 Full Professor of Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 Scientific Director of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Cardiology Dalton de Alencar Fischer Chamone, MD, PhD 4 Full Professor of Hematology and Hemotherapy, São Paulo University Medical School 4 PhD - Hematology and Hemottherapy, University of Louvain, Belgium 4 Associate Professor, São Paulo University Pharmaceutical Sciences School

Ari Timerman, MD, PhD 4 Assistant Professor of Cardiology, ABC Foundation School of Medicine, 4 PhD - Cardiology, São Paulo University Medical School 4 Head of the Emergency and Intensive Therapy Division, Dante Pazzanese Institute of Cardiology 4 President of the Cardiopulmonary Resuscitation Division of the Dante Pazzanese Institute of Cardiology 4 Head Professor of the TIC5007, Cardiovascular Emergencies of the Postgraduate Program USP/IDPC Medicine/Technology and Intervention in Cardiology Antonio Claudio Baruzzi, MD, PhD 4 PhD - Cardiology, Institute of the Heart, São Paulo University Medical School 4 Physician of the Intensive Care Center, Albert Einstein Hospital Fabio Santana Machado, MD 4 Medical Coordinator of the Neurosurgical ICU of the Neurosurgery, São Paulo University Medical School 4 Collaborator Professor of the Internal Medicine, São Paulo University Medical School 4 Physician of the Neuro-Intensive Care Unit, Sírio Libanês Hospital Hélio Penna Guimarães, MD 4 Assistant Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 President of the Chapter of Emergency Medicine of the Brazilian Society of Internal Medicine 4 Medical Coordinator, Teaching, Training and Simulation Center, Heart Hospital 4 Financial Director of the Brazilian Clinical Research Institute (BCRI)

Organization Support With unrestricted educational grant from Symposium Secretariat Caixa Postal: 19232 CEP: 04505 970 São Paulo SP + 55 11 3849 0379 Fax: + 55 11 3845 6818 www.meetingeventos.com.br info@meetingeventos.com.br